Literature DB >> 21510322

Investigation of serum tumor markers in the diagnosis of gastric cancer.

Biao Fan1, Bin Xiong.   

Abstract

BACKGROUND/AIMS: The purpose of this study was to evaluate the value of the tumor marker biochip C12 system in gastric cancer.
METHODOLOGY: A retrospective study of 183 patients with gastric cancer undergoing resection of gastric carcinoma was performed. Correlations between tumor markers and clinicopathologic features were evaluated univariately and multivariately. The most beneficial combination of key tumor markers in gastric cancer diagnosis was selected using chi-squared test.
RESULTS: The total positive rate of tumor markers for patients with gastric cancer was 42.6%. Multivariate logistic regression analysis revealed that the serum result of CA19-9 and CA125 were correlated with N stage, the serum result of CA242 was correlated with T stage and N stage, while the serum result of CEA was correlated with clinical stage and tumor histological differentiation (p < 0.05). Combinations of three tumor markers with high positive rates were CA242 + CEA + CA19-9 and CA242 + CEA + CA125, positive rates of which were 35.0% and 34.4% respectively with no statistical significance compared with twelve tumor markers combination (chi-squared test, p > 0.05).
CONCLUSION: The tumor marker biochip system has important diagnostic value in gastric cancer. CA19-9, CA242, CEA and CA125 were four key markers in tumor diagnosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21510322

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  14 in total

1.  At which stage of gastric cancer progression do levels of carcinoembryonic antigen and carbohydrate antigen 19-9 increase? Application in advanced gastric cancer treatment.

Authors:  Eui Soo Han; Han Hong Lee; Jun Suh Lee; Kyo Young Song; Cho Hyun Park; Hae Myung Jeon
Journal:  J Gastric Cancer       Date:  2014-06-30       Impact factor: 3.720

2.  Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer.

Authors:  Tsutomu Namikawa; Yasuhiro Kawanishi; Kazune Fujisawa; Eri Munekage; Jun Iwabu; Masaya Munekage; Hiromichi Maeda; Hiroyuki Kitagawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Surg Today       Date:  2017-10-17       Impact factor: 2.549

3.  Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon.

Authors:  Mirte M Streppel; Audrey Vincent; Radha Mukherjee; Nathaniel R Campbell; Shih-Hsun Chen; Konstantinos Konstantopoulos; Michael G Goggins; Isabelle Van Seuningen; Anirban Maitra; Elizabeth A Montgomery
Journal:  Hum Pathol       Date:  2012-04-26       Impact factor: 3.466

4.  LncRNA DRAIR is a novel prognostic and diagnostic biomarker for gastric cancer.

Authors:  Tian Jin
Journal:  Mamm Genome       Date:  2021-09-11       Impact factor: 2.957

5.  Nesfatin-1 is a potential diagnostic biomarker for gastric cancer.

Authors:  Xiao-Qing Wang; Yan Zheng; Pei-Fei Fang; Xian-Bing Song
Journal:  Oncol Lett       Date:  2019-12-10       Impact factor: 2.967

Review 6.  Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association.

Authors:  Hideaki Shimada; Tamaki Noie; Manabu Ohashi; Koji Oba; Yutaka Takahashi
Journal:  Gastric Cancer       Date:  2013-04-10       Impact factor: 7.370

7.  A Novel Electrochemical Microfluidic Chip Combined with Multiple Biomarkers for Early Diagnosis of Gastric Cancer.

Authors:  Yao Xie; Xiao Zhi; Haichuan Su; Kan Wang; Zhen Yan; Nongyue He; Jingpu Zhang; Di Chen; Daxiang Cui
Journal:  Nanoscale Res Lett       Date:  2015-12-10       Impact factor: 4.703

8.  Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer.

Authors:  Chao-Zhu He; Kun-He Zhang; Qing Li; Xiao-Hua Liu; Yan Hong; Nong-Hua Lv
Journal:  BMC Gastroenterol       Date:  2013-05-14       Impact factor: 3.067

9.  Clinical significance of the uPA system in gastric cancer with peritoneal metastasis.

Authors:  Youcheng Ding; Hui Zhang; Mingan Zhong; Zhuqing Zhou; Zhixiang Zhuang; Hua Yin; Xujing Wang; Zhenggang Zhu
Journal:  Eur J Med Res       Date:  2013-08-28       Impact factor: 2.175

10.  Serum biomarker panels for diagnosis of gastric cancer.

Authors:  Weihua Tong; Fei Ye; Liang He; Lifeng Cui; Miao Cui; Yuan Hu; Wei Li; Jing Jiang; David Y Zhang; Jian Suo
Journal:  Onco Targets Ther       Date:  2016-04-26       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.